4.7 Article

DNA Copy Number Alterations in Endobronchial Squamous Metaplastic Lesions Predict Lung Cancer

出版社

AMER THORACIC SOC
DOI: 10.1164/rccm.201102-0218OC

关键词

autofluorescence bronchoscopy; early detection; 3q; premalignant; follow-up studies

资金

  1. Dutch Cancer Society [KWF VU2007-3898]

向作者/读者索取更多资源

Rationale: Autofluorescence bronchoscopy (AFB) is a valid strategy for detecting premalignant endobronchial lesions. However, no biomarker can reliably predict lung cancer risk of subjects with AFB-visualized premalignant lesions. Objectives: The present study set out to identify AFB-visualized squamous metaplastic (SqM) lesions with malignant potential by DNA copy number profiling. Methods: Regular AFB examinations in 474 subjects at risk of lung cancer identified six subjects with SqM lesions at baseline, and carcinoma in situ or carcinoma (carcinoma in situ or greater) at the initial SqM site at follow-up bronchoscopy. These progressive SqM lesions were compared for immunostaining pattern and array comparative genomic hybridization-based chromosomal profiles with 23 SqM lesions of subjects who remained cancer-free. Specific DNA copy number alterations (CNAs) linked to cancer risk were identified and accuracy of CNAs to predict endobronchial cancer in this series was determined. Measurements and Main Results: At baseline, p53, p63, and Ki-67 immunostaining were not predictive for a differential clinical outcome of SqM lesions. The mean number of CNAs in baseline SqM of cases was significantly higher compared with control subjects (P < 0.01). Chromosomal regions significantly more frequently altered in SqM of cases were 3p26.3-p11.1, 3q26.2-q29, 9p13.3-p13.2, and 17p13.3-p11.2 (family-wise error rate <0.10). CNAs were specifically detected at the site of future cancer. In cases, baseline-detected CNAs persisted in subsequent biopsies taken from the initial site, and levels increased toward cancer progression. In this series, a model based on CNAs at 3p26.3-p11.1, 3q26.2-29, and 6p25.3-24.3 predicted cancer with 97% accuracy. Conclusions: The data suggest that the presence of specific CNAs in SqM lesions predict endobronchial cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells

Iris van 't Erve, Jamie E. Medina, Alessandro Leal, Eniko Papp, Jillian Phallen, Vilmos Adleff, Elaine Jiayuee Chiao, Adith S. Arun, Karen Bolhuis, John K. Simmons, Aanavi Karandikar, Kenneth C. Valkenburg, Mark Sausen, Samuel Angiuoli, Robert B. Scharpf, Cornelis J. A. Punt, Gerrit A. Meijer, Victor E. Velculescu, Remond J. A. Fijneman

Summary: The study demonstrates that accurate monitoring of treatment response using ctDNA can be achieved in a tumor tissue-independent manner by combining cfDNA and patient-matched WBC genomic DNA analysis. This approach prevents false-positives caused by germline or hematopoietic variants and provides more predictive information on overall survival compared to standard radiological evaluation. Additionally, ctDNA analysis reveals potential therapy resistance mutations in a significant portion of patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab

Sanne ten Hoorn, Linda Mol, Dirkje W. Sommeijer, Lisanne Nijman, Tom van den Bosch, Tim R. de Back, Bauke Ylstra, Erik van Dijk, Carel J. M. van Noesel, Roy J. Reinten, Iris D. Nagtegaal, Miriam Koopman, Cornelis J. A. Punt, Louis Vermeulen

Summary: We evaluated the potential efficacy of adding anti-EGFR therapy to anti-VEGF therapy in a subgroup of patients with metastatic colorectal cancer. The retrospective study (CAIRO2 trial, n = 736) showed no benefit of anti-EGFR addition within the subgroup, but an overall survival increase of 6.5 months compared to the original trial.

CLINICAL COLORECTAL CANCER (2023)

Article Pathology

A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice

Astrid Kramer, Ed Schuuring, Daan C. L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, Leon C. van Kempen, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Valesca P. Retel, Veerle M. H. Coup

Summary: This study developed a micro-costing framework for consistent cost calculation of ctDNA testing. The framework takes into account the complete diagnostic workflow of ctDNA testing, including costs for personnel, materials, equipment, overhead, and failures. Evaluations and case studies were performed, showing a wide range of costs per sample and the sensitivity to platform, setting, and testing volume. An open access tool is provided for laboratory-specific calculations and exploring the total costs and impact of alternative prices or assumptions.

JOURNAL OF MOLECULAR DIAGNOSTICS (2023)

Review Oncology

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Jan M. Van Rees, Lissa Wullaert, Alexander A. J. Grueter, Yassmina Derraze, Pieter J. Tanis, Henk M. W. Verheul, John W. M. Martens, Saskia M. Wilting, Geraldine Vink, Jeroen L. A. Van Vugt, Nick Beije, Cornelis Verhoef

Summary: This systematic review and meta-analyses demonstrate a strong association between ctDNA and recurrent disease in non-metastatic rectal cancer. ctDNA analysis can stratify patients into high and low risk groups for recurrence, especially when detected after neoadjuvant treatment and surgery. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer.

FRONTIERS IN ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Clonal Patterns Between Pouch Neoplasia and Prior Colorectal Neoplasia in Inflammatory Bowel Disease Patients: An Exploratory Cohort Study

Maarten te Groen, Lauranne A. A. P. Derikx, Lisa van Lierop, Bauke Ylstra, Frank Hoentjen, Iris D. Nagtegaal, Femke Simmer

Summary: The presence of previous colorectal neoplasia is the most significant indicator for the development of pouch neoplasia in inflammatory bowel disease. However, the underlying mechanism remains unknown. Our study found evidence of clonality between colorectal and pouch neoplasia in 30% of patients, suggesting that most pouch neoplasia develops independently from prior colorectal lesions.

INFLAMMATORY BOWEL DISEASES (2023)

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

False positivity in break apart fluorescence in-situ hybridization due to polyploidy

Anna Lena van Gulik, Ellen Sluydts, Liesbet Vervoort, Mark Kockx, Pim Kortman, Bauke Ylstra, Stephen P. Finn, Lukas Bubendorf, Idris Bahce, Daoud Sie, Teodora Radonic, Birgit Lissenberg-Witte, Erik Thunnissen

Summary: This study investigates the impact of cell size and ploidy on FISH results. The results show that in liver cell nuclei, the number of FISH signals increases with nuclear size and section thickness. In non-small cell lung cancer cases, tumor cells with higher ploidy levels and nuclear size have an increased chance of single signals. In addition, no rearrangements were found in lung cancer samples with borderline ALK FISH results, proving a false positive result.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Article Oncology

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients? Needs?

Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W. M. Martens, Saskia M. Wilting, Carin A. Uyl-de Groot, Agnes Jager

Summary: The addition of two years of abemaciclib treatment to high-risk ER+, HER2-early breast cancer patients has been approved by the FDA. Using detection of minimal residual disease (MRD) through patient-informed circulating tumor DNA assays, the addition of abemaciclib treatment shows cost-effectiveness for high-risk patients. However, adding abemaciclib to all high-risk patients is not cost-effective, while MRD-guided treatment is more cost-effective compared to standard treatment.

BREAST CANCER-TARGETS AND THERAPY (2023)

Article Oncology

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne

Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu

Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Pathology

Prognostic Value of T-Cell Density in the Tumor Center and Outer Margins in Gastric Cancer

Tanya T. D. Soeratram, Hedde D. Biesma, Jacqueline M. P. Egthuijsen, Elma Meershoek-Klein Kranenbarg, Henk H. Hartgrink, Cornelis J. H. van de Velde, Aart Mookhoek, Erik van Dijk, Yongsoo Kim, Bauke Ylstra, Hanneke W. M. van Laarhoven, Nicole C. T. van Grieken

Summary: Tumor-infiltrating lymphocytes are important for the survival of gastric cancer patients, and T-cell densities in different regions of the tumor can serve as prognostic markers. CD8OIM and FOXP3TC are identified as key factors for survival, and the combination of their densities can stratify patients into distinct subgroups with different prognosis. These immune subgroups are independent predictors for cancer-specific survival in resectable gastric cancer.

MODERN PATHOLOGY (2023)

Article Oncology

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Noortje Verschoor, Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, Annemieke van der Padt-pruijsten, Agnes Jager, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting

Summary: This study demonstrates that mFAST-SeqS can serve as a strong prognostic marker for MBC patients. It is an affordable and easily implementable method for assessing ctDNA levels, offering an alternative tool for prognosis. The aneuploidy score obtained using mFAST-SeqS is significantly correlated with CTC count and is a significant prognostic marker for both PFS and OS in MBC patients.

NPJ BREAST CANCER (2023)

Article Multidisciplinary Sciences

Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma

Margaretha G. M. Roemer, Tim van de Brug, Erik Bosch, Daniella Berry, Nathalie Hijmering, Phylicia Stathi, Karin Weijers, Jeannette Doorduijn, Jacoline Bromberg, Mark van de Wiel, Bauke Ylstra, Daphne de Jong, Yongsoo Kim

Summary: In order to understand the clinical relevance of the tumor microenvironment (TME), it is important to study the interactions between malignant and non-malignant cells in clinical samples. Researchers have developed a computational framework to comprehensively analyze the spatial context of the TME, including close and long-distance interactions between different cell types. This framework was applied to imaging data from 88 primary central nervous system lymphomas, revealing significant prognostic subgroups mainly determined by the spatial context. The results highlight the importance of spatial context in predicting patient survival, particularly in relation to macrophage infiltration near specific cell types.

ISCIENCE (2023)

Article Oncology

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol

D. M. Mens, J. M. van Rees, S. M. Wilting, C. Verhoef

Summary: Chemoradiation therapy (CRT) is the standard of care for treating rectal cancer, but it can cause damage to the surrounding healthy tissue and not all patients benefit from it. This study aims to develop a diagnostic innovation using DNA methylation to predict the effectiveness of CRT for rectal cancer patients.

BMC CANCER (2023)

Article Oncology

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer

Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W. M. Martens

Summary: In this study, the researchers investigated the characteristics and therapy resistance of HER2-positive breast cancer through integrating genomics and transcriptomics data. They found that the genomic profiles of primary and metastatic HER2-positive breast cancers were similar, and certain genomic features were predictive of progression-free survival on post-biopsy anti-HER2 treatment. Additionally, a HER2-driven expression profile grouped different types of HER2-positive tumors and indicated the possibility of transformation to ER independence. Integrated genomic and transcriptomic analyses may play a key role in establishing therapeutic options.

BREAST CANCER RESEARCH (2023)

暂无数据